Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03784911 · ClinicalTrials.gov registry record
Body Composition During Cancer Treatment
A clinical trial of Cancer, sponsored by Prisma Health-Upstate.
- Completed
- Registry status
- 51
- Enrollment target
- 1
- Study location
NCT03784911: Completed study of Cancer, sponsored by Prisma Health-Upstate.
NCT03784911 is a study of Cancer that has completed, run by Prisma Health-Upstate. The registered enrollment target is 51 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03784911, a study of Cancer, has completed, sponsored by Prisma Health-Upstate.
- COMPLETED
- Registry status
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess how bone density and body composition changes over a cancer patient's treatment via SOZO measurements, DEXA scan (bone density and whole body composition), performance status tests, food log, urine color test, and other study assessments. These assessments will begin after cancer diagnosis but prior to intervention, and continue during treatment and at post-treatment visits.
Primary Outcome
Assess change in body composition from baseline to final visit
Conditions Studied
Interventions
- DEVICE SOZO Device
- DEVICE DEXA Scan
Study Locations (1)
South Carolina
- Prisma Health Cancer Institute Center for Integrative Oncology and Survivorship - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-11-15 |
What the finished NCT03784911 record still lists
NCT03784911 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which SOZO Device is the first listed.
NCT03784911 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT03784911 about?
NCT03784911 is a clinical study titled "Body Composition During Cancer Treatment". The purpose of this study is to assess how bone density and body composition changes over a cancer patient's treatment via SOZO measurements, DEXA scan (bone density and whole body composition), performance status tests, food log, urine color test, and other study assessments. These assessments will...
What is the current status of trial NCT03784911?
This trial is currently completed. The enrollment target is 51 participants. The study started on 2018-10-01. Estimated completion is 2023-11-15.
What conditions does trial NCT03784911 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT03784911?
The interventions under investigation include: SOZO Device (DEVICE), DEXA Scan (DEVICE).
Who is sponsoring clinical trial NCT03784911?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03784911 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03784911's enrollment target sits among peer trials
51 420th of 615 higher than 195 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI